A Twelve-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study With Follow-up Evaluating The Safety And Efficacy Of Varenicline For Smoking Cessation In Healthy Adolescent Smokers

Trial Profile

A Twelve-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study With Follow-up Evaluating The Safety And Efficacy Of Varenicline For Smoking Cessation In Healthy Adolescent Smokers

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Mar 2018

At a glance

  • Drugs Varenicline (Primary)
  • Indications Smoking withdrawal
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 29 Mar 2018 New trial record
    • 23 Mar 2018 According to a Pfizer media release, company announce a topline results from this study.
    • 23 Mar 2018 Primary endpoint has not been met. (The 4-week continuous quit rate (CQR)), according to a Pfizer media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top